Equillium, Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 10, 2021 and accepted by EDGAR at Aug 10, 2021, 16:16 ET.
Management's discussion and analysis
As filed, 40,406 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December 31, 2020 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 24, 2021. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our” refer to Equillium, Inc.
Forward-Looking Statements
The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, “Risk Factors” in this Quarterly Report on Form 10-Q and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.
Overview
We are a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Our initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. Therefore, we believe itolizumab (EQ001) may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases.
Our pipeline is focused on developing itolizumab (EQ001) as a potential best-in-class, disease modifying treatment for multiple severe immuno-inflammatory disorders. We currently have active clinical development programs for itolizumab (EQ001) for the treatment of acute graft-versus-host disease, or aGVHD, lupus/lupus nephritis and uncontrolled asthma.
The EQUATE study is a Phase 1b/2 clinical trial of itolizumab (EQ001) for the first-line treatment of aGVHD. In June 2021, we announced positive topline results from the Phase 1b portion of the EQUATE study. In July 2021, we announced the completion of an End-of-Phase 1 meeting with the FDA which confirmed a path to advance itolizumab (EQ001) into a single Phase 3 pivotal study to support the Biologics License Application (BLA) filing for itolizumab (EQ001) in first-line treatment of patients with aGVHD. We plan to initiate the Phase 3 study in the fourth quarter of 2021.
The EQUIP study is a Phase 1b clinical trial of itolizumab (EQ001) for the treatment of uncontrolled asthma being conducted at sites in Australia and New Zealand. We plan to announce topline data from the EQUIP study in the second half of 2021.
The EQUALISE study is a Phase 1b proof-of-concept multiple ascending dose clinical trial of itolizumab (EQ001) for the treatment of lupus/lupus nephritis. The first part of the EQUALISE study is focused on evaluating the safety of itolizumab (EQ001) in patients with systemic lupus erythematosus (SLE) followed by a second part in lupus nephritis patients where, in addition to safety, potential clinical activity of itolizumab (EQ001) will be assessed. In March 2021, we reported favorable topline data from the Type A group of the EQUALISE study in patients with SLE. Through that topline data in the Type A group of the EQUALISE study, itolizumab (EQ001) administered subcutaneously was safe and well tolerated and demonstrated a dose-dependent reduction of cell surface CD6 expression on effector T cells, which is a leading indicator of drug activity, consistent with itolizumab's mechanism of action. We plan to announce interim data from the Type B part of the study in patients with lupus nephritis in the second half of 2021.
In March 2020, as a result of impacts and risks associated with the COVID-19 pandemic, we decided to pause enrollment in our EQUIP and EQUALISE studies. This decision was not based on any observed safety issues associated with itolizumab (EQ001) but rather out of an abundance of caution related to the COVID-19 pandemic and our concern for the well-being of patients and their caregivers. In July 2020, we announced that patient enrollment in both of those trials had resumed. We did not pause enrollment of patients in our EQUATE study given the acute life-threatening severity of aGVHD as we believe itolizumab (EQ001) represents a potentially life-saving treatment for these severely ill patients. However, there remains a risk that enrollment of all three of our current Phase 1b trials and the timing of data from those trials may be adversely impacted by the COVID-19 pandemic.
We acquired rights to itolizumab (EQ001) for the territories of the United States and Canada in May 2017 pursuant to a collaboration and license agreement with Biocon SA (subsequently assigned to Biocon Limited, or together, Biocon). In December 2019, we expanded our rights to itolizumab (EQ001) to include the territories of Australia and New Zealand pursuant to an amendment to that agreement. In August 2019, we entered into a letter agreement with Biocon that grants us exclusive rights to negotiate licensing rights with third parties to develop and commercialize itolizumab (EQ001) in select major markets outside of North America. This letter agreement allows us to represent itolizumab (EQ001) more broadly commercially and participate in value that may be created with strategic partners across geographies. Our collaboration with Biocon includes an exclusive supply agreement for clinical and commercial drug product of itolizumab (EQ001). Biocon currently manufactures itolizumab (EQ001) at commercial scale in a facility in India regulated by the FDA.
We have ongoing translational biology programs to assess the therapeutic potential of itolizumab (EQ001) in additional indications where CD6 and its ligand, Activated Leukocyte Cell Adhesion Molecule, or ALCAM, play an important role in the pathogenesis of T cell mediated diseases. Our selection of current and future indications is driven by our analysis of the scientific, translational, clinical and commercial rationale for advancing itolizumab (EQ001) into further development.
Since our inception, substantially all of our efforts have been focused on organizing and staffing our company, business planning, raising capital, in-licensing rights to itolizumab (EQ001), conducting non-clinical research, filing three INDs, conducting clinical development of itolizumab (EQ001) and the general and administrative activities associated with operating a public company. We have not generated any revenue from product sales or otherwise. Since inception, we have primarily financed our operations through our initial public offering, or IPO, a follow-on public offering, a registered direct offering, private placements of convertible promissory notes, term loans and sales of our common stock through “at-the-market” sales agreements, or ATM offerings, with Jefferies LLC, or Jefferies. We have incurred losses since our inception. Our net losses were $18.1 million for the six months ended June 30, 2021 and $29.8 million for the year ended December 31, 2020. As of June 30, 2021, we had an accumulated deficit of $89.1 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development activities, non-clinical and clinical activities and general and administrative costs associated with our operations.
We expect to continue to incur significant expenses and increasing losses into the foreseeable future. We anticipate our expenses will increase substantially as we continue our research and development activities, including the ongoing and future clinical development of itolizumab (EQ001), potentially expand the indications in which we conduct clinical development of itolizumab (EQ001), potentially acquire additional products and/or product candidates, seek regulatory approval for and potentially commercialize any approved product candidates, hire additional personnel, protect our intellectual property, incur increasing expense associated with our outstanding debt, and incur general corporate costs. We expect that our existing cash, cash equivalents and short-term investments as of June 30, 2021, will enable us to fund our currently planned operations for at least the next 12 months.
We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for itolizumab (EQ001) or any future product candidate, which is unlikely to happen within the next 12 months, if ever. Accordingly, until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through a combination of equity offerings, debt financings, and collaboration and license agreements. However, we may not be able to secure additional financing or enter into such other arrangements in a timely manner or on favorable terms, if at all. As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive. In addition, subject to limited exceptions, our loan and security agreement with Oxford Finance LLC and Silicon Valley Bank also prohibits us from incurring indebtedness without the prior written consent of the lenders, which consent may be withheld at their sole and absolute discretion. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, reduce or terminate our research and development programs or other operations, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
Financial Overview
Revenue
We currently have no products approved for sale, and we have not generated any revenues to date. In the future, we may generate revenue from collaboration or license agreements we may enter into with respect to our product candidates, as well as product sales from any approved product, which approval is unlikely to happen within the next 12 months, if ever. Our ability to generate product revenues will depend on the successful development and eventual commercialization of itolizumab (EQ001) and any future product candidates. If we fail to complete the development of itolizumab (EQ001) or any future product candidates in a timely manner, or to obtain regulatory approval for our product candidates, our ability to generate future revenue and our results of operations and financial position would be materially adversely affected.
Research and Development Expenses
Research and development expenses primarily consist of costs associated with our non-clinical research and clinical development of itolizumab (EQ001). Our research and development expenses include:
salaries and other related costs, including stock-based compensation and benefits, for personnel in research and development functions;
external research and development expenses incurred under arrangements with third parties, such as consultants and advisors for research and development;
costs of services performed by third parties, such as contract research organizations, or CROs, that conduct research and development activities on our behalf;
costs related to preparing and filing three INDs with the FDA and other regulatory interactions and submissions;
pharmacovigilance costs related to global drug safety monitoring and reporting;
external expenses related to chemistry, manufacturing, and controls (CMC) and supply of drug product; and
costs related to general overhead expenses such as travel, insurance and rent expenses associated with our research and development activities.
We expense research and development costs as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received.
Our direct research and development expenses consist principally of external costs, such as fees paid to CROs and consultants in connection with our non-clinical research and clinical development.
We recognize the Australian Research and Development Tax Incentive, or the Tax Incentive, as a reduction of research and development expense. The amounts are determined based on our eligible research and development expenditures and are non-refundable, provided that in order to qualify for the Tax Incentive the filing entity must have revenue of less than AUD $20.0 million during the tax year for which a reimbursement claim is made and cannot be controlled by an income tax exempt entity. The Tax Incentive is recognized when there is reasonable assurance that the Tax Incentive will be received, the relevant expenditure has been incurred, and the amount can be reliably measured or reliably estimated.
We plan to substantially increase our research and development expenses for the foreseeable future as we continue to advance the development of itolizumab (EQ001) and potentially expand the number of indications for which we are developing itolizumab (EQ001). The successful development of itolizumab (EQ001) is highly uncertain. At this time, due to the inherently unpredictable nature of pre-clinical and clinical development, which has been further exacerbated by the uncertain magnitude, extent and duration of impacts associated with the COVID-19 pandemic, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of itolizumab (EQ001) or the period, if any, in which material net cash inflows from itolizumab (EQ001) may commence. Clinical development timelines, the probability of success, and development costs can differ materially from expectations.
Completion of clinical trials may take several years or more, and the length of time generally varies according to the type, complexity, novelty, and intended use of a product candidate. The cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:
managing the impact of COVID-19 pandemic and related precautions on the operation of our clinical trials;
per patient clinical trial costs;
the number of clinical trials required for approval;
the number of sites and the number of countries included in our clinical trials;
the length of time required to enroll suitable patients;
the inefficiencies and additional costs related to any delays and potential restarts of clinical trials;
the number of doses that patients receive;
the number of patients that participate in our clinical trials;
the drop-out or discontinuation rates of patients in our clinical trials;
the duration of patient follow-up;
potential additional safety monitoring or other studies requested by regulatory agencies;
the number and complexity of procedures, analyses and tests performed during our clinical trials;
the costs of procuring drug product for our clinical trials;
the phase of development of the product candidate; and
the efficacy and safety profile of the product candidate.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation and benefits, and consulting fees for executive, human resources, investor relations, finance, and accounting functions. Other significant costs include legal fees relating to patent and corporate matters, insurance, travel, board expenses, facility costs and taxes.
We anticipate that our general and administrative expenses will increase in future periods, reflecting an expanding infrastructure, increased legal, audit, tax and other professional fees associated with being a public company and maintaining compliance with stock exchange listing and SEC requirements, director and officer insurance premiums associated with being a public company, and accounting and investor relations costs. In addition, if we obtain regulatory approval for any product candidate, we expect to incur expenses associated with building the infrastructure and capabilities to commercialize such product. However, the timing of any such approval is highly uncertain, and it may be several years, if ever, that we receive any such regulatory approval.
Interest Expense
Interest expense consists of interest and amortization of discounts on our outstanding term loans payable.
Interest Income
Interest income consists primarily of interest income earned on cash, cash equivalents and short-term investments, and is recognized when earned.
Other (Expense) Income, net
Other (expense) income, net consists primarily of net foreign currency transaction gains and losses related to our Australian subsidiary.
Results of Operations
Comparison of the Three and Six Months Ended June 30, 2021 and 2020
The following table sets forth our results of operations for the three and six months ended June 30, 2021 and 2020 (in thousands):
| Three Months Ended June 30, 2021 | 2020 | Six Months Ended June 30, 2021 | 2020 | |
|---|---|---|---|---|
| Research and development | $5,985 | $3,893 | $11,865 | $8,599 |
| General and administrative | 2,858 | 2,717 | 5,673 | 5,463 |
| Interest expense | (270) | (274) | (541) | (547) |
| Interest income | 13 | 122 | 39 | 342 |
| Other (expense) income, net | (58) | 301 | (109) | (31) |
17
Research and Development Expenses
Research and development expenses were $6.0 million and $11.9 million for three and six months ended June 30, 2021, respectively, compared to $3.9 million and $8.6 million for the three and six months ended June 30, 2020, respectively.
The increase of $2.1 million in research and development expenses for the three months ended June 30, 2021, compared to the same period in 2020, was primarily driven by the following changes:
$0.9 million increase in employee compensation and benefits, primarily related to increased headcount;
$0.7 million increase in clinical development activities, primarily related to our aGVHD and lupus/lupus nephritis clinical trials;
$0.2 million increase in consulting activities;
$0.2 million increase in overhead expenses primarily driven by increased lab supplies and costs associated with expansion of lab space; and
$0.1 million increase in non-clinical research activities.
The increase of $3.3 million in research and development expenses for the six months ended June 30, 2021, compared to the same period in 2020, was primarily driven by the following changes:
$1.5 million increase in employee compensation and benefits, primarily related to increased headcount;
$1.4 million increase in clinical development activities, primarily related to our aGVHD and lupus/lupus nephritis clinical trials;
$0.2 million increase in non-clinical research activities;
$0.1 million increase in consulting activities; and
$0.1 million increase in overhead expenses primarily driven by increased lab supplies and costs associated with expansion of lab space.
General and Administrative Expenses
General and administrative expenses were $2.9 million and $5.7 million for the three and six months ended June 30, 2021, respectively, compared to $2.7 million and $5.5 million for the three and six months ended June 30, 2020, respectively.
The increase of $0.2 million in general and administrative expenses for the three months ended June 30, 2021, compared to the same period in 2020, was primarily driven by the following changes:
$0.4 million increase in employee compensation and benefits, primarily related to increased headcount; and
$0.2 million decrease in non-cash stock-based compensation mainly due to fully-vested retention option grants issued to certain officers and directors in the second quarter of 2020.
The increase of $0.2 million in general and administrative expenses for the six months ended June 30, 2021, compared to the same period in 2020, was primarily driven by the following changes:
$0.7 million increase in employee compensation and benefits, primarily related to increased headcount;
$0.2 million decrease in consulting expenses;
$0.2 million decrease in legal fees; and
$0.1 million decrease in overhead expenses primarily driven by lower insurance costs.
Interest Expense
Interest expense was $0.3 million and $0.5 million for the three and six months ended June 30, 2021, respectively, compared to $0.3 million and $0.5 million in the same periods in 2020. Interest expense consists of interest on our term notes payable.
Interest Income
Interest income was $13,000 and $39,000 for the three and six months ended June 30, 2021, respectively, compared to $0.1 million and $0.3 million for the three and six months ended June 30, 2020, respectively. The decrease in interest income was primarily due to lower interest rates during 2021 compared to 2020.
Other (Expense) Income, net
Other expense, net was $0.1 million for the three and six months ended June 30, 2021, respectively, compared to $0.3 million of other income, net and $31,000 of other expense, net for the three and six months ended June 30, 2020. The change in both the three and six months ended June 30, 2021 compared to the same periods in 2020 were primarily driven by changes in net foreign currency transaction gains and losses.
Liquidity and Capital Resources
From inception through June 30, 2021, we have raised an aggregate of approximately $178.1 million in gross proceeds pursuant to our IPO, a follow-on public offering, a registered direct offering, private placements of convertible promissory notes, proceeds from term loans and proceeds from equity issuances under our ATM facility. As of June 30, 2021, we had $73.5 million in cash and cash equivalents and $24.1 million in short-term investments.
Sources of Liquidity
Registered Direct Offering
In February 2021, we entered into a securities purchase agreement with two institutional investors relating to the issuance and sale of an aggregate of 4,285,710 shares of common stock and warrants to purchase 1,285,713 shares of common stock for aggregate gross proceeds to us from this offering of approximately $30.0 million, excluding any proceeds we may receive upon exercise of the warrants. No underwriter or placement agent participated in the offering. The warrants are exercisable immediately upon issuance at an initial exercise price of $14.00 per share and are exercisable on a cashless basis. The warrants expire on the earlier of (i) the fifth anniversary of issuance or (ii) the 15th calendar date following the date on which we close upon an equity financing that results in not less than $25 million in gross proceeds to us at a price per share of common stock equal to or greater than $25.00, at which time, all remaining warrants will automatically exercise on a cashless basis.
Follow-on Public Offering
In August 2020, we completed an underwritten public offering of 5,461,169 shares of common stock at $7.00 per share, which included 461,169 shares sold pursuant to the exercise of the underwriters’ option to purchase additional shares. We received gross proceeds from this offering totaling $38.2 million. Net proceeds from this offering, net of underwriting discounts and related issuance costs, were $35.7 million.
2020 Purchase Agreement
In March 2020, we entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions and limitations set forth therein, we may sell to Lincoln Park up to $15.0 million of shares of our common stock from time to time over the 36-month term of the Purchase Agreement. Upon execution of the Purchase Agreement, we issued 65,374 shares of our common stock to Lincoln Park as commitment shares in accordance with the closing conditions contained within the Purchase Agreement. We have not sold any shares of our common stock to Lincoln Park under the Purchase Agreement through the date of the filing of this Quarterly Report on Form 10-Q.
At-the-Market Offering Program
In November 2019, we entered into an Open Market Sales AgreementSM with Jefferies to sell shares of our common stock having aggregate sales proceeds of up to $8.45 million, from time to time, through an ATM equity offering program under which Jefferies acts as sales agent, or the 2019 ATM Facility. Under the 2019 ATM Facility, we set certain parameters for the sale of shares, which may include but are not limited to the number of shares to be issued, the time period during which sales are requested to be made, and any minimum price below which sales may not be made. Jefferies is entitled to compensation for its services at a commission rate of 3.0% of the gross sales price per share of common stock sold plus reimbursement of certain expenses. As of July 2020, the 2019 ATM Facility had been fully utilized. We sold an aggregate of 943,739 shares of our common stock under the 2019 ATM Facility for gross proceeds of $8.45 million.
On July 14, 2020, we entered into another Open Market Sales Agreement with Jefferies for a new ATM equity offering to sell shares of our common stock, from time to time, having aggregate sales proceeds of up to $150 million under which Jefferies would act as sales agent, or the 2020 ATM Facility. The 2020 ATM Facility provides that Jefferies will be entitled to compensation for its services at a commission rate of 3.0% of the gross sales price per share of common stock sold. We are not obligated to make any sales under the 2020 ATM Facility. As of June 30, 2021, we sold an aggregate of 788,685 shares of common stock under the 2020 ATM Facility, for gross proceeds of $10.4 million. We paid cash commissions on the gross proceeds, plus reimbursement expenses to Jefferies, legal fees and other issuance costs in the aggregate amount of $0.4 million, resulting in net proceeds of $10.0 million. There have been no further sales of shares under the 2020 ATM Facility through the date of the filing of this Quarterly Report on Form 10-Q.
September 2019 Loan Agreement
On September 30, 2019, we entered into a loan and security agreement, or Loan Agreement, with Oxford Finance LLC and Silicon Valley Bank, or together, the Lenders, pursuant to which we can borrow up to $20.0 million in a series of term loans. Upon entering into the Loan Agreement, we borrowed $10.0 million, or Term A Loan. Under the terms of the Loan Agreement, we may, at our sole discretion, borrow from the Lenders (i) up to an additional $5.0 million, or Term B Loan, upon our achievement of positive topline data in either our (a) itolizumab (EQ001) Phase 1b aGVHD trial or (b) itolizumab (EQ001) Phase 1b asthma trial, supporting a formal decision to advance into Phase 2 development, and as confirmed by our Board of Directors, or the Term B Milestone, and (ii) up to an additional $5.0 million, or Term C Loan and together with Term A Loan and Term B Loan, the Term Loans, upon our achievement of positive topline data in both our EQ001 Phase 1b aGVHD trial and our itolizumab (EQ001) Phase 1b asthma trial, supporting a formal decision to advance into Phase 2 development, and as confirmed by our Board of Directors, or the Term C Milestone. We may draw the Term B Loan during the period commencing on the date of the occurrence of the Term B Milestone and ending on the earliest of (i) December 31, 2020, (ii) 60 days after achieving the Term B Milestone, and (iii) the occurrence of an event of default. We may draw the Term C Loan during the period commencing on the date of the occurrence of the Term C Milestone and ending on the earliest of (i) December 31, 2020, (ii) 60 days after achieving the Term C Milestone, and (iii) the occurrence of an event of default. As of December 31, 2020, the Company did not achieve the Term B or Term C Milestone and was not eligible to receive the additional funding up to $10.0 million under the Loan Agreement.
All of the Term Loans mature on June 1, 2024 (the Maturity Date) and are repaid through interest-only payments through June 30, 2021, followed by 36 equal monthly payments of principal and interest. The Term Loans bear interest at a floating per annum rate equal to the greater of (i) 8.25% and (ii) the sum of (a) the prime rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (b) 3.00%.
On December 18, 2020, the Company entered into the First Amendment to the Loan Agreement (the First Amendment) with the Lenders whereby if the Company achieves the Term B Milestone on or prior to June 30, 2021, the interest-only payments will be automatically extended through December 31, 2021.
On April 23, 2021, the Company entered into the Second Amendment to the Loan Agreement (the Second Amendment) which added two new milestones: (i) the Company achieving positive data in the Company's Phase 1b aGVHD trial of itolizumab (EQ001) supporting a formal decision to advance into Phase 2 or Phase 3 development, and as confirmed by the Company's Board of Directors in written board minutes (the Interest-Only Extension Milestone) and (ii) the Company initiating a pivotal Phase 3 aGVHD trial (the Interest-Only Extension II Milestone). If the Company achieves the Interest-Only Extension Milestone on or prior to June 30, 2021, then interest-only payments will be automatically extended through June 30, 2022. If the Company achieves the Interest-Only Extension II Milestone on or prior to June 30, 2022, then interest-only payments will be automatically extended through September 30, 2022. The Second Amendment also amended the final payment percentage from 4.5% to 5.0%.
In May 2021, the Company achieved the Interest-Only Extension Milestone. Due to the achievement of the Interest-Only Extension Milestone, the interest-only payments have been extended through June 30, 2022, followed by 24 equal monthly principal payments and interest. The Company has not achieved the Interest-Only Extension II Milestone as of June 30, 2021 and through the date of the filing of this Quarterly Report on Form 10-Q.
Funding Requirements
We expect our expenses to increase substantially in connection with our ongoing and future activities, particularly as we advance and expand our clinical development of itolizumab (EQ001), including potential new indications. We expect that our primary uses of capital will be for clinical research and development services, non-clinical research, manufacturing, legal and other regulatory compliance expenses, compensation and related expenses, risk management, and general overhead costs.
We expect that our existing cash, cash equivalents and short-term investments as of June 30, 2021 will enable us to fund our currently planned operations for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Furthermore, our operating plans may change, and we may need additional funds sooner than planned. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress in these trials is uncertain. Because the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of itolizumab (EQ001) or whether, or when, we may achieve profitability.
Our future capital requirements will depend on many factors, including:
the initiation, progress, timing, costs and results of our ongoing and future clinical trials of itolizumab (EQ001), including as such activities may be adversely impacted by the COVID-19 pandemic;
the number and scope of indications we decide to pursue for itolizumab (EQ001) development;
the cost, timing and outcome of regulatory review of any Biologics License Application, or BLA, we may submit for itolizumab (EQ001);
the costs and timing of manufacturing for itolizumab (EQ001), if approved;
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of itolizumab (EQ001);
the costs associated with operating a public company;
the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
the extent to which we acquire or in-license other product candidates and technologies; and
the cost associated with commercializing itolizumab (EQ001), if approved for commercial sale.
Until such time as we can generate substantial product revenues, if ever, we expect to finance our cash needs through a combination of equity offerings, debt financings, and collaboration and license agreements. The sale of additional equity or convertible debt could result in additional dilution to our stockholders and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. The incurrence of debt financing would result in debt service obligations and the governing documents would likely include operating and financing covenants that would restrict our operations. As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive. If we raise additional funds through collaboration or license agreements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or other operations. Any of these actions could have a material effect on our business, financial condition and results of operations. We have experienced net losses and negative cash flows from operating activities since our inception and expect to continue to incur net losses into the foreseeable future. We had an accumulated deficit of $89.1 million as of June 30, 2021. We expect operating losses and negative cash flows to continue for at least the next several years as we continue to incur costs related to the development of itolizumab (EQ001).
Cash Flows
The following table sets forth the primary sources and uses of cash for each of the periods set forth below (in thousands):
| Net cash provided by (used in): | Six Months Ended June 30, 2021 | 2020 |
|---|---|---|
| Operating activities | $(14,938) | $(11,450) |
| Investing activities | 33,827 | 21,460 |
| Financing activities | 30,662 | 871 |
| Effect of exchange rate changes on cash | (8) | (17) |
| Net increase in cash and cash equivalents | $49,543 | $10,864 |
Operating Activities
Net cash used in operating activities was $14.9 million during the six months ended June 30, 2021 as compared to $11.5 million during the six months ended June 30, 2020. The increase in net cash used in operating activities was primarily the result of the increase in operating expenses during the six months ended June 30, 2021 related to a ramp up in our research and clinical development activities.
Investing Activities
Net cash provided by investing activities was $33.8 million during the six months ended June 30, 2021. We purchased $7.6 million of short-term investments, and $41.5 million of our short-term investments matured during the period. Purchases of property and equipment for the six months ended June 30, 2021 totaled $23,000.
Net cash provided by investing activities was $21.5 million during the six months ended June 30, 2020. We purchased $2.2 million of short-term investments, and $23.7 million of our short-term investments matured during the period. Purchases of property and equipment for the six months ended June 30, 2020 totaled $15,000.
Financing Activities
Net cash provided by financing activities totaled $30.7 million during the six months ended June 30, 2021. We received net proceeds from the sale of shares associated with our registered direct offering. totaling $29.9 million as well as from the exercise of stock options totaling $0.6 million and from the issuance of shares under our employee stock purchase plan totaling $0.1 million.
Net cash provided by financing activities totaled $0.9 million during the six months ended June 30, 2020. We received net proceeds from the sale of shares under the 2019 ATM facility totaling $0.8 million and from the issuance of shares under our employee stock purchase plan totaling $0.1 million.
Off-Balance Sheet Arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules, and similarly did not and do not have any holdings in variable interest entities.
Controls and procedures
As filed, 2,381 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
As of June 30, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2021.
There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 172 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes from the risk factors as previously disclosed in Part I, Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2020.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2021-04-01 to 2021-06-30 | $6.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $11.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$8.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$17.5m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2021-04-01 to 2021-06-30 | −$9.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | −$18.1m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | −$14.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $23.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-06-30 | $73.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $99.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $99.8m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $5.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $15.1m | us-gaap:Liabilities |
| Long-term debt | At period end2021-06-30 | $10.1m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2021-06-30 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2021-06-30 | $84.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-21-001180. Last ingested by Listed: Nov 14, 2026, 19:43 ET. Listed shows no prices and gives no investment advice.